Phase 2 Thyroid Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You have been diagnosed with a specific type of thyroid cancer (called differentiated thyroid cancer, or DTC) — including papillary, follicular, or Hürthle cell thyroid cancer — confirmed by a tissue sample test.
• Your cancer cannot be cured and has stopped responding to radioactive iodine (RAI) treatment, meaning it either does not absorb the treatment, has gotten worse during or after RAI, you have received a very high total dose of RAI, or you are unable or unwilling to have surgery or RAI.
• Your cancer can be measured or tracked on scans according to standard medical guidelines.
• You have received no more than one previous treatment targeting a specific type of cancer growth pathway (called VEGF/VEGFR therapy — examples include sorafenib or cabozantinib).
• Your cancer is causing symptoms or has been getting worse on your most recent treatment over the last 16 months.
• You are at least 18 years old.
• You are generally able to care for yourself and carry out light activity (your doctor will assess this using a standard scale).
• Your blood pressure reading at screening is below 140/90 (retesting is allowed if needed).
• Your blood counts, liver function, kidney function, heart rhythm, and urine protein levels are within acceptable ranges as measured by blood and urine tests (confirm specific values with trial site).
• If you could become pregnant, or if you are a man who could father a child, you must agree to use reliable contraception during the trial and for 30 days after the last dose of the study drug.
• You are able to understand the study and are willing to sign a consent form (a legal representative may do this on your behalf if needed).

Who may not be able to join:

• You have a different type of thyroid cancer, such as anaplastic, poorly differentiated/high-grade, or medullary thyroid cancer.
• You have previously been treated with the study drug, lenvatinib.
• You have another cancer that could interfere with how your safety or response to treatment is assessed.
• You are currently taking part in another clinical trial involving an experimental treatment.
• You have brain metastases (cancer that has spread to the brain) that have not yet been treated — though treated brain metastases may be allowed if scans show no further growth after treatment.
• You have had a serious allergic reaction to a drug similar to lenvatinib or other drugs used in this study.
• You are currently taking certain medications known to affect heart rhythm in a risky way (a washout period of 7 days may be allowed if you stop that medication before starting the trial).
• You have an uncontrolled illness such as an active serious infection, severe heart failure, unstable chest pain, or irregular heart rhythm — or your heart function falls below a certain level as assessed by your doctor.
• You are pregnant or breastfeeding, or you are a woman of childbearing age with a positive pregnancy test within 14 days of starting the trial.
• You have HIV and are not on effective treatment with an undetectable virus level for at least the past 6 months (HIV testing is only needed if you have a known history of HIV).
• You have chronic hepatitis B with a detectable viral level, even on treatment (testing only needed if you have a known history of hepatitis B).
• You have hepatitis C that has not been successfully treated or still has a detectable viral level (testing only needed if you have a known history of hepatitis C).
• You have had major surgery within 14 days before starting the trial, or any surgical wound that has not fully healed.

Important: Always verify eligibility with the trial site directly before applying.